Biosimilars at 20: the next chapter is about access
An Expert View from Shreehas Tambe, CEO and Managing Director, Biocon (NSE: BIOCON).
This year marks 20 years since Europe approved its first biosimilar. It is both a moment to recognize the progress made and to reflect on the potential that remains untapped. Since the European Medicines Agency (EMA) approved the first biosimilar in 2006, these medicines have delivered 6.9 billion patient treatment days, 1 generated billions in savings and now account for 12% of the total volume of biologic treatments in Europe. 2 That is a remarkable shift in healthcare delivery, and one few could have predicted two decades ago.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
| Headless Content Management with Blaze